Nirogacestat Receives European Approval for Treatment of Desmoid Tumors
Written by
Cancer Network
Published
0
comments
0
min
The EC decision is based on phase 3 DeFi trial results, in which nirogacestat met the primary end point of PFS in patients with progressing desmoid tumors.